Dermatology
ASLAN Pharmaceuticals focuses its clinical research on atopic dermatitis, with attention to patients living with persistent inflammatory skin disease and ongoing symptom burden.
- Moderate-to-severe atopic dermatitis
- Inflammatory skin disorders
- Chronic pruritic disease
The sponsor’s current research activity is centered on treatment options for individuals who have previously received dupilumab, reflecting interest in difficult-to-manage dermatologic disease.
Immunology
The company’s trial portfolio is directed toward immune-mediated skin inflammation, with emphasis on pathways relevant to eczema and related immune dysregulation.
- Immune-mediated inflammation
- Skin barrier dysfunction
- Allergic inflammation
Its research activity is aligned with conditions where immune signaling contributes to persistent cutaneous symptoms and disease severity.
Biologic Therapy
ASLAN Pharmaceuticals is involved in clinical evaluation of biologic therapy for chronic inflammatory disease, with a focus on targeted treatment approaches in dermatology.
- Targeted immunomodulation
- Monoclonal antibody therapy
- Advanced therapeutic antibodies
The sponsor’s research interest lies in therapies designed to address patients whose disease remains active despite prior advanced treatment.
Refractory Disease Management
Its clinical work includes patients with treatment-experienced atopic dermatitis, highlighting interest in disease that has not been adequately controlled by earlier therapy.
- Prior biologic exposure
- Persistent disease activity
- Unmet dermatologic need
This area reflects attention to individuals requiring additional therapeutic options after previous systemic treatment.
